Afimmune
- Biotech or pharma, therapeutic R&D
Afimmune's lead asset Epeleuton is a near term approval opportunity for a novel, oral therapy for Sickle Cell Disease (rare).
***Not accepting CRO/CMO/Consultant meetings at this time, thank you***
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}